Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://www.nature.com/articles/s41408-018-0095-2.pdf
Reference7 articles.
1. Tefferi, A. et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124, 2507–2513 (2014).
2. Tefferi, A. et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia 32, 1200–1210 (2018).
3. Samuelson Bannow, B. T. et al. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. Biol. Blood Marrow Transplant. 24, 386–392 (2017).
4. Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (IARC, Lyon, France, 2017).
5. Tefferi, A. et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood 118, 4595–4598 (2011).
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy;Clinical Lymphoma Myeloma and Leukemia;2024-09
2. Challenging Scenarios in the Management of Myeloproliferative Neoplasms;Clinical Lymphoma Myeloma and Leukemia;2024-09
3. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era;Blood Advances;2024-06-28
4. Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN;Blood Advances;2024-03-04
5. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It;Clinical Lymphoma Myeloma and Leukemia;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3